Concord Biotech's Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Concord Biotech Ltd reported a 10.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.1%.
- Its expenses for the quarter were up by 11.6% QoQ and 23.8% YoY.
- The net profit increased 0.9% QoQ and decreased 16.2% YoY.
- The earnings per share (EPS) of Concord Biotech Ltd stood at 6.08 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 287.74 | 260.41 | 258.95 | 10.5% | 11.1% |
Total Expenses | 197.62 | 177.02 | 159.63 | 11.6% | 23.8% |
Profit Before Tax | 86.85 | 83.39 | 99.32 | 4.1% | -12.6% |
Tax | 22.51 | 22.62 | 25.23 | -0.5% | -10.8% |
Profit After Tax | 63.64 | 63.06 | 75.92 | 0.9% | -16.2% |
Earnings Per Share | 6.08 | 6.03 | 7.26 | 0.8% | -16.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Concord Biotech Ltd is a prominent player in the biotechnology industry, primarily engaged in the development and production of biopharmaceutical products. The company specializes in manufacturing active pharmaceutical ingredients (APIs) and formulations, catering to various therapeutic segments. Concord Biotech is known for its strong research and development capabilities, which have led to a robust product pipeline. However, specific details about recent major developments were not provided in the data. Concord Biotech operates in a highly competitive and regulated industry, where innovation and compliance with global standards are critical for success.
Revenue
In the third quarter of fiscal year 2026, Concord Biotech Ltd reported a total income of ₹287.74 crores. This marks a quarter-over-quarter increase of 10.5% from ₹260.41 crores in the second quarter of fiscal year 2026. The year-over-year growth compared to the third quarter of fiscal year 2025, when total income was ₹258.95 crores, is 11.1%. The company's revenue growth both on a quarterly and annual basis points towards an upward trend in income generation during this period.
Profitability
For Q3FY26, Concord Biotech Ltd recorded a profit before tax of ₹86.85 crores, which shows a quarter-over-quarter increase of 4.1% from ₹83.39 crores in Q2FY26. However, this figure represents a year-over-year decline of 12.6% from ₹99.32 crores in Q3FY25. The tax expense for Q3FY26 was ₹22.51 crores, slightly lower by 0.5% compared to Q2FY26 and 10.8% lower than Q3FY25. The profit after tax for Q3FY26 was ₹63.64 crores, reflecting a minimal quarter-over-quarter rise of 0.9% from ₹63.06 crores in Q2FY26, but a year-over-year decrease of 16.2% from ₹75.92 crores in Q3FY25. Earnings per share in this quarter were ₹6.08, a marginal increase of 0.8% from Q2FY26, yet a decrease of 16.3% compared to Q3FY25.
Operating Metrics
Total expenses for Concord Biotech Ltd in Q3FY26 amounted to ₹197.62 crores, representing an increase of 11.6% quarter-over-quarter from ₹177.02 crores in Q2FY26. On a year-over-year basis, expenses increased by 23.8% from ₹159.63 crores in Q3FY25. This rise in expenses was significant compared to the rise in total income. Key financial ratios, such as the P/E ratio and debt-to-equity ratio, are not provided in the data, and thus could not be calculated. The current ratio also could not be determined due to the lack of necessary balance sheet data. The earnings per share, a critical metric for investors, was ₹6.08 in Q3FY26, showing a minor improvement from the previous quarter but a decline compared to the same quarter in the previous year. These metrics provide a detailed view of the company's operational performance over the specified period.